Metastatic castration-resistant prostate cancer Trials in San Francisco, United States
Conditions / Metastatic castration-resistant prostate cancer / San Francisco, United States
Metastatic castration-resistant prostate cancer has been the subject of sustained clinical investigation across multiple research sites.
37 total trials for this combination
Showing top 10 of 37 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06691984 | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | RECRUITING | PHASE3 |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | COMPLETED | PHASE1 |
| NCT06764485 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | RECRUITING | PHASE3 |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | COMPLETED | PHASE1 |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | RECRUITING | — |
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | TERMINATED | PHASE1 |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | RECRUITING | PHASE1/PHASE2 |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT02952534 | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | COMPLETED | PHASE2 |
| NCT05519449 | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | RECRUITING | PHASE1 |